Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Models of Health Promotion and Illness Prevention I01:25

Models of Health Promotion and Illness Prevention I

A model is a theoretical way to understand a concept or an idea. Models can overcome barriers to health regardless of diverse economic and cultural backgrounds. In addition, models make the task easier by providing different ways to approach complex issues. There are two major health promotion models: the health belief model and the health promotion model.
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
Models of Health Promotion and Illness Prevention II01:18

Models of Health Promotion and Illness Prevention II

The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results from...
Clearance Models: Noncompartmental Models01:17

Clearance Models: Noncompartmental Models

Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. However, a noncompartmental model offers an alternative method for assessing clearance, primarily employing empirical data obtained after administering a single drug dose.
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...
Clearance Models: Physiological Models01:09

Clearance Models: Physiological Models

Drug clearance is a critical pharmacokinetic process involving the irreversible removal of drugs from the body through various organs over a specified time period. Physiological models are indispensable in determining organ-specific clearance, defined by the proportion of the drug eliminated per unit of time from the organ's blood volume.
The organ's clearance rate depends on the blood flow to the organ and the extraction ratio (E). The extraction ratio describes the organ's proficiency in drug...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mortality among U.S. Industrial Radiographers Exposed to Ionizing Radiation, 1969-2019.

Radiation research·2026
Same author

Colossus: bridging the gap between big data and radiation epidemiology.

Journal of radiological protection : official journal of the Society for Radiological Protection·2025
Same author

Cancer Mortality after Protracted Low-level Radiation Exposure for Early and Contemporary Workers in Two Large Occupational Cohorts in the U.S. Million Person Study.

Radiation research·2025
Same author

Colossus: software for radiation epidemiological studies with big data.

Journal of radiological protection : official journal of the Society for Radiological Protection·2025
Same author

Approaches to harmonize mortality data sets in three diverse radiation worker cohorts.

Journal of radiological protection : official journal of the Society for Radiological Protection·2025
Same author

Distribution of plutonium and radium in the human heart.

Journal of radiological protection : official journal of the Society for Radiological Protection·2024
Same journal

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same journal

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same journal

Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026
Same journal

Welcome reduction of US cervical cancer rates despite state differences.

Journal of the National Cancer Institute·2026
Same journal

Adjuvant dual HER2 blockade along the HER2-ER axis in APHINITY.

Journal of the National Cancer Institute·2026
Same journal

Re: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Journal of the National Cancer Institute·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Models, models everywhere--is there a fit for lifetime risks?

John D Boice

    Journal of the National Cancer Institute
    |October 27, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Establishing a Competing Risk Regression Nomogram Model for Survival Data
    04:57

    Establishing a Competing Risk Regression Nomogram Model for Survival Data

    Published on: October 23, 2020

    Related Experiment Videos

    Last Updated: Jun 7, 2026

    An R-Based Landscape Validation of a Competing Risk Model
    05:37

    An R-Based Landscape Validation of a Competing Risk Model

    Published on: September 16, 2022

    Establishing a Competing Risk Regression Nomogram Model for Survival Data
    04:57

    Establishing a Competing Risk Regression Nomogram Model for Survival Data

    Published on: October 23, 2020